Amicus Therapeutics, Inc.
FOLD
Rankning i aktier
#3708
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Aktiekurs
$14.49
Senast synkroniserad: 2026-04-27
Marknadsvärde
$4.55B
Förändring (1 dag)
0.00%
Förändring (1 år)
71.68%
Land
US
Handel Amicus Therapeutics, Inc. (FOLD)
Kategori
Healthcare
P/B-tal för Amicus Therapeutics, Inc. (FOLD)
P/B-tal per October 2026 TTM: 16.33
Enligt Amicus Therapeutics, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 16.33. I slutet av 2023 hade företaget ett P/B-tal på 26.15.
Historik för P/B-tal för Amicus Therapeutics, Inc. från 2003 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 16.33 | 10.47% |
| 2024 | 14.78 | -43.49% |
| 2023 | 26.15 | -8.84% |
| 2022 | 28.68 | 181.23% |
| 2021 | 10.20 | -51.13% |
| 2020 | 20.87 | 324.64% |
| 2019 | 4.92 | -5.30% |
| 2018 | 5.19 | -17.01% |
| 2017 | 6.25 | 237.21% |
| 2016 | 1.85 | -39.50% |
| 2015 | 3.07 | -39.53% |
| 2014 | 5.07 | 92.44% |
| 2013 | 2.63 | 49.32% |
| 2012 | 1.76 | -56.10% |
| 2011 | 4.02 | 100.18% |
| 2010 | 2.01 | 60.55% |
| 2009 | 1.25 | -50.51% |
| 2008 | 2.53 | 83.43% |
| 2007 | 1.38 | -1,105.40% |
| 2006 | -0.14 | -17.07% |
| 2005 | -0.17 | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | -0.84 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -61.72% |
US
|
|
| 13.2547 | -18.82% |
US
|
|
| 4.208 | -74.23% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -62.14% |
NL
|
